Literature DB >> 14624391

Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations.

Christina L Liquori1, Michel J Berg, Adrian M Siegel, Elizabeth Huang, Jon S Zawistowski, T'Prien Stoffer, Dominique Verlaan, Fiyinfolu Balogun, Lori Hughes, Tracey P Leedom, Nicholas W Plummer, Milena Cannella, Vittorio Maglione, Ferdinando Squitieri, Eric W Johnson, Guy A Rouleau, Louis Ptacek, Douglas A Marchuk.   

Abstract

Cerebral cavernous malformations (CCMs) are congenital vascular anomalies of the central nervous system that can result in hemorrhagic stroke, seizures, recurrent headaches, and focal neurologic deficits. Mutations in the gene KRIT1 are responsible for type 1 CCM (CCM1). We report that a novel gene, MGC4607, exhibits eight different mutations in nine families with type 2 CCM (CCM2). MGC4607, similar to the KRIT1 binding partner ICAP1alpha, encodes a protein with a phosphotyrosine-binding domain. This protein may be part of the complex pathway of integrin signaling that, when perturbed, causes abnormal vascular morphogenesis in the brain, leading to CCM formation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14624391      PMCID: PMC1180409          DOI: 10.1086/380314

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  24 in total

1.  Linkage to the CCM2 locus and genetic heterogeneity in familial cerebral cavernous malformation.

Authors:  Nicolas Dupré; Dominique J Verlaan; Collette K Hand; Sandra B Laurent; Gustavo Turecki; W Jeptha Davenport; Nicola Acciarri; Johannes Dichgans; Akio Ohkuma; Adrian M Siegel; Guy A Rouleau
Journal:  Can J Neurol Sci       Date:  2003-05       Impact factor: 2.104

2.  Familial cavernous angiomas of the brain: observations in a four generation family.

Authors:  E Steichen-Gersdorf; S Felber; W Fuchs; L Russeger; K Twerdy
Journal:  Eur J Pediatr       Date:  1992-11       Impact factor: 3.183

3.  Cerebral cavernous malformations. Incidence and familial occurrence.

Authors:  D Rigamonti; M N Hadley; B P Drayer; P C Johnson; K Hoenig-Rigamonti; J T Knight; R F Spetzler
Journal:  N Engl J Med       Date:  1988-08-11       Impact factor: 91.245

4.  Mapping a gene causing cerebral cavernous malformation to 7q11.2-q21.

Authors:  M Günel; I A Awad; J Anson; R P Lifton
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

5.  A gene responsible for cavernous malformations of the brain maps to chromosome 7q.

Authors:  J Dubovsky; J M Zabramski; J Kurth; R F Spetzler; S S Rich; H T Orr; J L Weber
Journal:  Hum Mol Genet       Date:  1995-03       Impact factor: 6.150

6.  Familial cerebral cavernous angioma: clinical analysis of a family and phenotypic classification.

Authors:  A Gil-Nagel; K J Wilcox; J M Stewart; V E Anderson; I E Leppik; S S Rich
Journal:  Epilepsy Res       Date:  1995-05       Impact factor: 3.045

7.  Mutation and expression analysis of the KRIT1 gene associated with cerebral cavernous malformations (CCM1).

Authors:  Hildegard Kehrer-Sawatzki; Monika Wilda; Veit M Braun; Hans-Peter Richter; Horst Hameister
Journal:  Acta Neuropathol       Date:  2002-06-26       Impact factor: 17.088

8.  Krit1/cerebral cavernous malformation 1 mRNA is preferentially expressed in neurons and epithelial cells in embryo and adult.

Authors:  C Denier; J-M Gasc; F Chapon; V Domenga; C Lescoat; A Joutel; E Tournier-Lasserve
Journal:  Mech Dev       Date:  2002-09       Impact factor: 1.882

9.  Angiographically occult vascular malformations: a correlative study of features on magnetic resonance imaging and histological examination.

Authors:  F H Tomlinson; O W Houser; B W Scheithauer; T M Sundt; H Okazaki; J E Parisi
Journal:  Neurosurgery       Date:  1994-05       Impact factor: 4.654

10.  The natural history of familial cavernous malformations: results of an ongoing study.

Authors:  J M Zabramski; T M Wascher; R F Spetzler; B Johnson; J Golfinos; B P Drayer; B Brown; D Rigamonti; G Brown
Journal:  J Neurosurg       Date:  1994-03       Impact factor: 5.115

View more
  133 in total

1.  Molecular recognition of leucine-aspartate repeat (LD) motifs by the focal adhesion targeting homology domain of cerebral cavernous malformation 3 (CCM3).

Authors:  Xiaofeng Li; Weidong Ji; Rong Zhang; Ewa Folta-Stogniew; Wang Min; Titus J Boggon
Journal:  J Biol Chem       Date:  2011-06-01       Impact factor: 5.157

Review 2.  Pathogenesis of vascular anomalies.

Authors:  Laurence M Boon; Fanny Ballieux; Miikka Vikkula
Journal:  Clin Plast Surg       Date:  2011-01       Impact factor: 2.017

3.  Systems biology and proteomic analysis of cerebral cavernous malformation.

Authors:  Alexander R Edelmann; Sarah Schwartz-Baxter; Christopher F Dibble; Warren C Byrd; Jim Carlson; Ivandario Saldarriaga; Sompop Bencharit
Journal:  Expert Rev Proteomics       Date:  2014-03-31       Impact factor: 3.940

4.  CCM1 gene deletion identified by MLPA in cerebral cavernous malformation.

Authors:  Sabine Gaetzner; Sonja Stahl; Oguzkan Sürücü; Anne Schaafhausen; Birgit Halliger-Keller; Helmut Bertalanffy; Ulrich Sure; Ute Felbor
Journal:  Neurosurg Rev       Date:  2006-12-23       Impact factor: 3.042

5.  Identification of two novel mutations and of a novel critical region in the KRIT1 gene.

Authors:  Vito Guarnieri; Lucia A Muscarella; Rosina Amoroso; Alessandro Quattrone; Massimo E Abate; Michelina Coco; Domenico Catapano; Vincenzo A D'Angelo; Leopoldo Zelante; Leonardo D'Agruma
Journal:  Neurogenetics       Date:  2006-10-17       Impact factor: 2.660

Review 6.  Endogenous endothelial cell signaling systems maintain vascular stability.

Authors:  Nyall R London; Kevin J Whitehead; Dean Y Li
Journal:  Angiogenesis       Date:  2009-01-27       Impact factor: 9.596

Review 7.  Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology.

Authors:  Oriana S Fisher; Titus J Boggon
Journal:  Cell Mol Life Sci       Date:  2013-11-29       Impact factor: 9.261

8.  ccm2-like is required for cardiovascular development as a novel component of the Heg-CCM pathway.

Authors:  Jonathan N Rosen; Vanessa M Sogah; Lillian Y Ye; John D Mably
Journal:  Dev Biol       Date:  2013-01-15       Impact factor: 3.582

Review 9.  Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling.

Authors:  Bryan T Richardson; Christopher F Dibble; Asya L Borikova; Gary L Johnson
Journal:  Biol Chem       Date:  2013-01       Impact factor: 3.915

10.  Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.

Authors:  Christopher C Gibson; Weiquan Zhu; Chadwick T Davis; Jay A Bowman-Kirigin; Aubrey C Chan; Jing Ling; Ashley E Walker; Luca Goitre; Simona Delle Monache; Saverio Francesco Retta; Yan-Ting E Shiu; Allie H Grossmann; Kirk R Thomas; Anthony J Donato; Lisa A Lesniewski; Kevin J Whitehead; Dean Y Li
Journal:  Circulation       Date:  2014-12-08       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.